Hydrocortisone Renata Pharmaceuticals (Ireland)

Hydrocortisone Renata Pharmaceuticals (Ireland) is an oral tablet containing the corticosteroid hydrocortisone. It is supplied in a prescription‑only format and conforms to European Union pharmaceutical standards. The product provides systemic glucocorticoid activity for conditions requiring hormone replacement or anti‑inflammatory therapy. While the exact strength and tablet size are not specified in the public label, the active ingredient is hydrocortisone, a naturally occurring adrenal hormone commonly used in clinical practice.

Hydrocortisone Renata Pharmaceuticals is prescribed for several endocrine and inflammatory conditions where glucocorticoid replacement or suppression is needed.

- Primary adrenal insufficiency (Addison’s disease) requiring cortisol replacement. - Congenital adrenal hyperplasia to compensate for deficient cortisol synthesis. - Acute adrenal crisis as emergency hormone support. - Inflammatory disorders such as severe allergic reactions, asthma exacerbations, or rheumatic disease flares. - Certain dermatologic or ophthalmic conditions when systemic therapy is indicated.

Adverse reactions to oral hydrocortisone vary in frequency and severity.

Common: - Increased appetite or weight gain. - Fluid retention leading to mild edema. - Elevated blood glucose or transient hyperglycemia. - Mood changes such as irritability or insomnia. - Gastrointestinal discomfort, nausea, or dyspepsia.

Serious: - Suppression of the hypothalamic‑pituitary‑adrenal axis causing adrenal insufficiency on abrupt withdrawal. - Severe hypertension or worsening of pre‑existing cardiovascular disease. - Osteoporosis or increased risk of fractures with long‑term use. - Opportunistic infections due to immunosuppression. - Psychiatric disturbances including psychosis or severe depression.

Before initiating hydrocortisone therapy, clinicians should evaluate several safety considerations.

- Assess for active infections; glucocorticoids can exacerbate bacterial, viral, or fungal diseases. - Screen for uncontrolled diabetes, hypertension, or osteoporosis, as hydrocortisone may worsen these conditions. - Use the lowest effective dose and taper gradually to avoid adrenal crisis. - Monitor growth in pediatric patients receiving long‑term therapy. - Counsel patients on the risk of electrolyte imbalance, particularly sodium retention and potassium loss. - Avoid abrupt discontinuation after prolonged use without medical supervision.

Hydrocortisone can alter the pharmacokinetics or pharmacodynamics of several other medicines.

Avoid: - Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce hydrocortisone exposure. - Concurrent use of systemic immunosuppressants (e.g., cyclosporine) without dose adjustment, increasing infection risk.

Use with caution: - Anticoagulants (warfarin) as glucocorticoids may enhance anticoagulant effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) because of additive gastrointestinal ulcer risk. - Diabetic agents (insulin, oral hypoglycemics) due to potential hyperglycemia. - Vaccines, especially live attenuated, because of immunosuppression. - Diuretics, which may potentiate electrolyte disturbances.